Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
IDWeek: Ending HIV as an epidemic will demand innovation, inclusion, an expanded workforce — and funding
As the federal Ending the HIV epidemic takes form, experts talk details, challenges: “How do we get there from here?” WASHINGTON, DC – Nearly four decades […]
Patients treated for multidrug-resistant tuberculosis with an experimental regimen containing a repurposed drug for a year had similar rates of successful outcomes as patients treated with […]
While a World Health Organization-led strategy aims to provide 1.4 billion doses of vaccine against yellow fever to achieve 80% vaccination coverage across countries by 2026 […]
The following is a guest post By Sharon Weir, Ph.D. of MEASURE Evaluation The Priorities for Local AIDS Control Efforts — PLACE –method aims to improve […]